Eisai's Rufinamide Estimated User Fee Deadline Is July 2006

The company submitted its NDA for the anti-epileptic on Sept. 9 for the orphan indication of adjunctive therapy for Lennox-Gastaut syndrome and for adjunctive therapy for partial-onset seizures.